Neuropsychiatric (NP) Sxs compared in SLE (n 609), controls (463) & IA patients (489). Hallucinations and severe headache were most directly attributable to NP-SLE. https://t.co/JWbyHmpWcq https://t.co/gBubdEjq63

• Neuropsychiatric symptoms in Systemic Lupus Erythematosus: mixed methods analys…

337 PMR pts studied by FDG PET, followed 6 mos - 9% (31) had subclinical vasculitis (GCA) - 21 had isolated LG vessel - 3 isolated cranial vasculitis - 7 both cranial & LG vessel vasculitis. Steroid use higher w/ subclinical vasculitis, but not relapse https://t.co/uwXf4ucVnQ https://t.co/AOacTnQZaS

• Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalg…

How do you communicate risk/benefit to patients? @RADoctor's recent publication highlighted by Dr. H. Gabalawy at #RNL2024 -Increase awareness -Include numbers for context - Make it easy for patients to understand those numbers -Use absolute risks - Avoid 1 in X format

Aging in RA: "(RA is due to a poorly functioning immune system which increases a patients risk of CVD, infection, and cancer. The aging immune system additionally affects this process.

We must consider this clinically, we must protect our aging patients without over immunosuppressing them." Dr. Weyand #RNL2024

H2H study of secukinumab vs adalimumab biosimilar in axial-SpA pts saw no difference & little change in Xray progression for both Rxs. 859 pts showed no signif diff w/ NO Xray progr (66%, 67%, 66%) or mSASSS (0.54, 0.55, 0.72) change https://t.co/QqB1aCjfN7 https://t.co/Ktfi7xVoC6

• Effect of secukinumab versus adalimumab biosimilar on radiographic progression …

Polycyclic Aromatic Hydrocarbons Increase Lupus Risk A case-controlled study shows environmental exposure to polycyclic aromatic hydrocarbons (PAH) may increase the risk of developing systemic lupus erythematosus (SLE). https://t.co/kztA4s5UY3 https://t.co/QJ6DXXCBh8

• Polycyclic Aromatic Hydrocarbons Increase Lupus Risk | RheumNow

We're back again on 4/9 with another Tuesday Night Rheumatology! We'll be focusing on PsA Hot Topics. Register to attend today! https://t.co/Ssbv020MOi https://t.co/qL6EGegCVf

• RheumNow.com

10 SLE pts w/ ITP and thrombocytopenia were Rx w/ belimumab IV (age 34.3 ± 14 yrs). Overall response rate of thrombocytopenia was 90%, w/ improvement in platelets, lymphocyte count, Hgb, dsDNA, C3, C4 and SLEDAI https://t.co/0IXjqXa8lS https://t.co/pNiu4TCnky

• The use of belimumab on patients with both systemic lupus erythematosus and imm…

Among 3.2 million people who starting opioids, there were 506 573 serious fall, esp w/ increasing age; Opioid use associated with increased risk of serious falls, esp. if >85 yrs (adj IRR 6.35) and within the first 28 days of commencing opioid use https://t.co/IifmEE9Q5n https://t.co/N2PkLofA4r

• Age-Related Fall Risk and Opioid Analgesic Use

Oral Surveillance study revisited: the risk of Venous thromboembolism & Pulmonary emboli were higher with tofacitinib (10>5 mg BID) versus TNFi and were generally consistent over time. VTE & PE risk incr by age, BMI, and VTE Hx https://t.co/v7ISjw5Rvd https://t.co/10oE7MiAAj

• Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor In…

"#RNL2024 Brittany Weber on Cardio-Rheumatology: ""Everything has changed"" on inflammation and CVD - Canakinumab 150 mg v PBO HR 0.85, p =0.02 - Colchicine v PBO HR 0.69, P<0.001 2023: FDA approval for colchicine as 1st anti-inflammatory for reducing CV events

#RNL2024 @RheumNow @Bweber04 Asymptomatic Lupus has higher rate of atherosclerosis at all age grps 35-44 yo F with SLE: 50X increased risk of MI compared to healthy pts in Framingham RA pts at 1.5x risk of CVD https://t.co/wL4U8Gh5JM

• https://buff.ly/4aEue3n